Compare SBGI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | CMPX |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 926.7M |
| IPO Year | 1995 | N/A |
| Metric | SBGI | CMPX |
|---|---|---|
| Price | $14.97 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $21.00 | $13.44 |
| AVG Volume (30 Days) | 362.1K | ★ 2.1M |
| Earning Date | 02-25-2026 | 03-18-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,337,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.89 | $1.33 |
| 52 Week High | $17.88 | $6.88 |
| Indicator | SBGI | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 54.00 |
| Support Level | $14.37 | $6.05 |
| Resistance Level | $15.30 | $6.82 |
| Average True Range (ATR) | 0.57 | 0.38 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 82.34 | 26.51 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.